FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2057961427> ?p ?o ?g. }

• W2057961427 endingPage "663" @default.
• W2057961427 startingPage "663" @default.
• W2057961427 abstract "Oral anticoagulant therapy is dangerous, with 1–2% of patients suffering a major haemorrhage each year ( Palareti et al, 1996 ). Two mutations that are associated with haemorrhage in patients treated with warfarin have been described at Ala-10 in the factor IX propeptide, i.e. Ala to Thr ( Chu et al, 1996 ; Oldenburg et al, 1997 ) and Ala to Val ( Oldenburg et al, 1997 ). These mutations interfere with a recognition site for γ-glutamylcarboxylase, the enzyme that carboxylates the glutamic acids in the gla-domain. This means that when warfarin therapy is given to maintain a therapeutic International Normalized Ratio (INR), with factors VII, X and prothrombin 20–40% of normal, the factor IX level falls to < 3%. These reports raised the question of whether male patients on warfarin should have an activated partial thromboplastin time (aPTT) screening test. In our anticoagulant clinic, we decided against this after Peters et al (1997 ) screened 750 patients (412 males) and found no cases, and we simply resolved to measure the aPTT in patients who haemorrhaged without an excessive INR. This policy was recently supported by another group ( van der Meer et al, 1999 ), who screened 734 patients and again found no cases. We report a further case. A 56-year-old man presented with an axillary vein thrombosis secondary to carcinoma of the stomach. He was initiated on warfarin therapy, but suffered extensive bruising and a right leg haematoma within 4 weeks of commencement. His INR was consistently maintained between 2 and 3 but his aPTT was disproportionately prolonged, ranging from 104 to 170 s [normal range (NR) 22–34 s]. When his INR was 2.2, his factor VII level was 20 u/dl (NR 50–150 u/dl) and his factor IX level < 1 u/dl (NR 50–150 u/dl). The warfarin was discontinued, his bruising stopped and the factor IX level rose to 65 u/dl. Sequencing of the patient's factor IX gene revealed the G6346A mutation that results in the Ala-10→Thr substitution. Problems due to mutations at Ala-10 are likely to be manifest soon after warfarin therapy is initiated, therefore the screening of long-term stable patients may be selecting against the likelihood of finding these mutations which may not be so rare as supposed. This case shows that the aPTT should be measured in patients on warfarin who bleed despite a therapeutic INR, and one should be particularly vigilant soon after treatment is initiated. If this problem is identified, warfarin must be discontinued. Vitamin K will normalize coagulation, but if more urgent reversal is required for serious haemorrhage then prothrombin complex concentrates are likely to be more effective than FFP in a patient with very low levels of factor IX. In patients who need continued anticoagulation, we would recommend using low molecular weight heparin. Family studies should be undertaken to identify other male carriers of the mutation so that they can be warned of the risk of anticoagulant therapy." @default.
• W2057961427 created "2016-06-24" @default.
• W2057961427 creator A5012522749 @default.
• W2057961427 creator A5063885274 @default.
• W2057961427 creator A5067997735 @default.
• W2057961427 creator A5088720234 @default.
• W2057961427 date "2000-03-01" @default.
• W2057961427 modified "2023-09-27" @default.
• W2057961427 title "ALA-10 MUTATIONS IN THE FACTOR IX PROPEPTIDE AND HAEMORRHAGE IN A PATIENT TREATED WITH WARFARIN" @default.
• W2057961427 cites W2042366680 @default.
• W2057961427 cites W2075531913 @default.
• W2057961427 cites W2104651850 @default.
• W2057961427 cites W2150666115 @default.
• W2057961427 doi "https://doi.org/10.1046/j.1365-2141.2000.01901.x" @default.
• W2057961427 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/10847705" @default.
• W2057961427 hasPublicationYear "2000" @default.
• W2057961427 type Work @default.
• W2057961427 sameAs 2057961427 @default.
• W2057961427 citedByCount "6" @default.
• W2057961427 countsByYear W20579614272019 @default.
• W2057961427 crossrefType "journal-article" @default.
• W2057961427 hasAuthorship W2057961427A5012522749 @default.
• W2057961427 hasAuthorship W2057961427A5063885274 @default.
• W2057961427 hasAuthorship W2057961427A5067997735 @default.
• W2057961427 hasAuthorship W2057961427A5088720234 @default.
• W2057961427 hasBestOaLocation W20579614271 @default.
• W2057961427 hasConcept C126322002 @default.
• W2057961427 hasConcept C141071460 @default.
• W2057961427 hasConcept C2776301958 @default.
• W2057961427 hasConcept C2778205648 @default.
• W2057961427 hasConcept C2778261982 @default.
• W2057961427 hasConcept C2778382381 @default.
• W2057961427 hasConcept C2779161974 @default.
• W2057961427 hasConcept C2780434524 @default.
• W2057961427 hasConcept C2780868729 @default.
• W2057961427 hasConcept C2780930249 @default.
• W2057961427 hasConcept C2781221834 @default.
• W2057961427 hasConcept C71924100 @default.
• W2057961427 hasConcept C90924648 @default.
• W2057961427 hasConceptScore W2057961427C126322002 @default.
• W2057961427 hasConceptScore W2057961427C141071460 @default.
• W2057961427 hasConceptScore W2057961427C2776301958 @default.
• W2057961427 hasConceptScore W2057961427C2778205648 @default.
• W2057961427 hasConceptScore W2057961427C2778261982 @default.
• W2057961427 hasConceptScore W2057961427C2778382381 @default.
• W2057961427 hasConceptScore W2057961427C2779161974 @default.
• W2057961427 hasConceptScore W2057961427C2780434524 @default.
• W2057961427 hasConceptScore W2057961427C2780868729 @default.
• W2057961427 hasConceptScore W2057961427C2780930249 @default.
• W2057961427 hasConceptScore W2057961427C2781221834 @default.
• W2057961427 hasConceptScore W2057961427C71924100 @default.
• W2057961427 hasConceptScore W2057961427C90924648 @default.
• W2057961427 hasIssue "3" @default.
• W2057961427 hasLocation W20579614271 @default.
• W2057961427 hasLocation W20579614272 @default.
• W2057961427 hasOpenAccess W2057961427 @default.
• W2057961427 hasPrimaryLocation W20579614271 @default.
• W2057961427 hasRelatedWork W152325395 @default.
• W2057961427 hasRelatedWork W1979587511 @default.
• W2057961427 hasRelatedWork W1984114947 @default.
• W2057961427 hasRelatedWork W2024491237 @default.
• W2057961427 hasRelatedWork W2073621733 @default.
• W2057961427 hasRelatedWork W2119075172 @default.
• W2057961427 hasRelatedWork W2153897808 @default.
• W2057961427 hasRelatedWork W2332753980 @default.
• W2057961427 hasRelatedWork W3105412849 @default.
• W2057961427 hasRelatedWork W3022441607 @default.
• W2057961427 hasVolume "108" @default.
• W2057961427 isParatext "false" @default.
• W2057961427 isRetracted "false" @default.
• W2057961427 magId "2057961427" @default.
• W2057961427 workType "article" @default.